The FDA has so far approved four botanical products, with a view to greenlight more. Credit: Svetliy/Shutterstock.com. The US Food and Drug Administration (FDA) is requesting public input on both the ...

Ionis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease “in the coming weeks”.

The FDA's latest efforts to curb the illicit US medicines trade are primarily centred around weight loss and fat-reducing peptides.

Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks.

Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, wh ...

Researchers call for further exploration of xylitol’s impact on heart health as its use in food and pharma continues to rise.

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.

At ESC 2026, a session presented by Dr Domenica Rubino covered the considerations to take into account when comparing oral and injectable formulations of GLP-1 therapies.

The Australia-based STAREE trial is the first of its kind demonstrating the preventative effects of statins in older patients.

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).